NCT06900114 2026-03-05
Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China
Institute of Hematology & Blood Diseases Hospital, China
Completed
Clinical Trials
19 trialsNCT07450833 2026-03-05
BOOST
Benfovir AG
Phase 1 Completed
NCT04407143 2026-02-09
SOLID
Fundación GECP
Completed
NCT05119855 2026-02-05
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04341012 2026-01-26
Breath Analysis Based Disease Biomarkers
Mayo Clinic
Completed
NCT07328399 2026-01-09
Impact of COVID-19 Pandemic Waves on Colorectal Cancer Stage Migration and Diagnostic Delays
University of Pecs
Completed
NCT04872738 2026-01-06
LymphVAX
Massachusetts General Hospital
Completed
NCT04421625 2025-12-30
PAPESCO-19
Institut Cancerologie de l'Ouest
Phase NA Completed
NCT04442048 2025-12-30
COV-IMMUNO
Canadian Cancer Trials Group
Phase 3 Completed
NCT04425616 2025-12-02
SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer
University Hospital Southampton NHS Foundation Trust
Phase NA Completed
NCT04830046 2025-11-26
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Massachusetts General Hospital
Completed
NCT04492410 2025-09-30
NEOSCREENCOVID
Centre Antoine Lacassagne
Phase NA Completed
NCT04427280 2025-09-04
CARDS
Royal Marsden NHS Foundation Trust
Completed
NCT05120869 2025-09-04
Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention
University of Texas, El Paso
Phase NA Completed
NCT04932863 2025-08-08
UNICO
Ente Ospedaliero Ospedali Galliera
Completed
NCT04870333 2025-06-20
PROTECT-V
Cambridge University Hospitals NHS Foundation Trust
Phase 2/3 Completed
NCT04848493 2025-06-13
VAX4FRAIL
Azienda USL Reggio Emilia - IRCCS
Completed
NCT06124131 2025-05-04
BENEFIT-C
Tulane University
Phase NA Completed
NCT04854980 2025-03-30
Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients
University of Rochester
Completed